Form 4: Castle Biosciences Director Daniel Bradbury Sells Shares Under 10b5-1 Plan

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on April 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 8, 2024, Daniel Bradbury, a director at Castle Biosciences, sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 23, 2023.
• Bradbury sold 761 shares directly at a weighted-average price of $20.453.
• Additionally, 819 shares held by the Daniel Bradbury Irrevocable Descendant's Trust and 820 shares held by the Annette Bradbury Irrevocable Descendant's Trust were sold at the same price.
• The transactions resulted in adjustments to the number of shares beneficially owned by Bradbury directly and indirectly through BioBrit, LLC, and the descendant's trusts.
• After the transactions, Bradbury directly owns 4,655 shares, BioBrit, LLC owns 42,516 shares, Daniel Bradbury Irrevocable Descendant's Trust owns 17,944 shares, and Annette Bradbury Irrevocable Descendant's Trust owns 17,948 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged plan and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.

Comparison to Industry Standards

• Comparing this transaction to other similar transactions is difficult without knowing the specific financial situation of Daniel Bradbury.
• However, sales under 10b5-1 plans are common among executives and directors of publicly traded companies.
• For example, executives at companies like Exact Sciences and Guardant Health also utilize 10b5-1 plans for regular stock sales.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates